Literature DB >> 29274042

Sclerosing Epithelioid Fibrosarcoma of the Jaw: Late Recurrence from a Low Grade Fibromyxoid Sarcoma.

Catherine Laliberte1,2, Iona T Leong1,2, Howard Holmes1,2, Eric A Monteiro3,4, Brian O'Sullivan5,6, Brendan C Dickson7,8.   

Abstract

Sclerosing epithelioid fibrosarcoma (SEF) is an uncommon variant of fibrosarcoma that is characterized by a distinct morphology. It most frequently presents in the deep soft tissues of the lower extremities, often in intimate association with fascia and periosteum, although reports of the head and neck involvement have been reported. A minority of cases show morphological, immunohistochemical and molecular overlap with low grade fibromyxoid sarcoma (LG-FMS). Herein, we describe a case of a bland spindle cell neoplasm presenting in the jaw that was initially incompletely excised. Over the course of 20 years the tumor subsequently recurred with a SEF morphology. Molecular testing performed on both specimens subsequently confirmed the presence of an EWSR1-CREB3L1 gene fusion. This report highlights the diagnostic difficulty with LG-FMS, particularly in unusual anatomic locations; reiterates the potential for the uncommon EWSR1-CREB3L1 fusion product in LG-FMS; and, reaffirms the potential for progression and/or overlap between LG-FMS to SEF over time.

Entities:  

Keywords:  Case report; EWSR1-CREB3L1; Jaw; Low-grade fibromyxoid sarcoma; Mandible; Sarcoma; Sclerosing epithelioid fibrosarcoma

Mesh:

Substances:

Year:  2017        PMID: 29274042      PMCID: PMC6232198          DOI: 10.1007/s12105-017-0879-x

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  20 in total

Review 1.  Low-Grade Fibromyxoid Sarcoma of the Head and Neck: A Clinicopathologic Series and Review of the Literature.

Authors:  Morgan L Cowan; Lester D Thompson; Marino E Leon; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2015-08-15

2.  Oral and maxillofacial sclerosing epithelioid fibrosarcoma: report of five cases.

Authors:  Gretchen S Folk; Stephen B Williams; Robert B Foss; Julie C Fanburg-Smith
Journal:  Head Neck Pathol       Date:  2007-10-26

3.  MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma.

Authors:  Leona A Doyle; Emely Möller; Paola Dal Cin; Christopher D M Fletcher; Fredrik Mertens; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

4.  Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor.

Authors:  C R Antonescu; M K Rosenblum; P Pereira; A G Nascimento; J M Woodruff
Journal:  Am J Surg Pathol       Date:  2001-06       Impact factor: 6.394

5.  Low-grade fibromyxoid sarcoma: a clinicopathologic study of 18 cases, including histopathologic relationship with sclerosing epithelioid fibrosarcoma in a subset of cases.

Authors:  Bharat Rekhi; Mahesh Deshmukh; Nirmala A Jambhekar
Journal:  Ann Diagn Pathol       Date:  2011-05-06       Impact factor: 2.090

6.  A primary sclerosing epithelioid fibrosarcoma of the pubic bone, with evidence of divergent epithelial differentiation.

Authors:  Guofeng Wang; Brian Eyden
Journal:  Ultrastruct Pathol       Date:  2010-04       Impact factor: 1.094

7.  Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene.

Authors:  Fredrik Mertens; Christopher D M Fletcher; Cristina R Antonescu; Jean-Michel Coindre; Maurizio Colecchia; Henryk A Domanski; Erinn Downs-Kelly; Cyril Fisher; John R Goldblum; Louis Guillou; Robin Reid; Juan Rosai; Raf Sciot; Nils Mandahl; Ioannis Panagopoulos
Journal:  Lab Invest       Date:  2005-03       Impact factor: 5.662

8.  EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma.

Authors:  Patrick P L Lau; Philip C W Lui; Gene T C Lau; Derek T W Yau; Elaine T Y Cheung; John K C Chan
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

9.  MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement.

Authors:  Leona A Doyle; Wei-Lien Wang; Paola Dal Cin; Dolores Lopez-Terrada; Fredrik Mertens; Alexander J F Lazar; Christopher D M Fletcher; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

Review 10.  Primary sclerosing epithelioid fibrosarcoma of the sacrum: a case report and review of the literature.

Authors:  L T C Chow; Y H Lui; S M Kumta; P W Allen
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

View more
  4 in total

Review 1.  Clinical and molecular characterization of primary sclerosing epithelioid fibrosarcoma of bone and review of the literature.

Authors:  Yusuke Tsuda; Brendan C Dickson; Sarah M Dry; Noah Federman; Albert J H Suurmeijer; David Swanson; Yun-Shao Sung; Lei Zhang; John H Healey; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2019-11-15       Impact factor: 5.006

2.  Case Report: Radiological Features of Sclerosing Epithelioid Fibrosarcoma in the Right Fibula.

Authors:  Qiaoling Ding; Xiaotong Shao; Xiaocao Liu; Yanbiao Fu; Fengbo Huang; Chao Wang
Journal:  Front Oncol       Date:  2020-11-18       Impact factor: 6.244

3.  A case of cellular variants of Sclerosing epithelioid fibrosarcoma resembling Plasmacytoma/Myeloma: Diagnostic difficulty in the fine needle aspiration.

Authors:  Nahoko Nagano; Noriyoshi Ishikawa; Mamiko Nagase; Asuka Araki; Teruaki Iwahashi; Riruke Maruyama
Journal:  Int J Surg Case Rep       Date:  2020-03-07

Review 4.  Metastatic pediatric sclerosing epithelioid fibrosarcoma.

Authors:  Andrew D Woods; Charles Keller; Aman Wadhwa; Reshma Purohit; Laura Crocker Mitchell; John R Collier; Katherine A Collier; Melvin Lathara; Katrina Learned; Olena Vaske; Heather Geiger; Kazimierz O Wrzeszczynski; Vaidehi Jobanputra; Ganapati Srinivasa; Erin R Rudzinski; Kimberly Whelan; Elizabeth Beierle; Sheri L Spunt
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-10-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.